

25 February 2010

Darren Collins
Senior Adviser, Issuers and Accounting Policy
Australian Stock Exchange
525 Collins Street
Melbourne 3000

By email: darren.collins@asx.com.au

Dear Darren

Sigma Pharmaceuticals Limited – Request for Trading Halt

Pursuant to Listing Rule 17.1, Sigma Pharmaceuticals Limited (ACN 088 417 403) (ASX: SIP) ("**Sigma**") requests that the ASX grant a trading halt of its securities effective immediately.

For the purposes of ASX Listing Rule 17.1, Sigma provides the following information:

- 1 the trading halt is necessary as Sigma expects to make an announcement to the market in relation to revised earnings guidance arising from year end adjustments.
- 2 Sigma expects that the trading halt remain in place until the commencement of normal trading on 1 March 2010, unless, before that time, Sigma makes an announcement concerning revised earnings guidance or requests that the trading halt be lifted;
- 3 Sigma expects to make an announcement to the market concerning the revised earnings guidance before the commencement of trading on 1 March 2010; and
- 4 Sigma is not aware of any reason why the trading halt should not be granted.

If you have any queries, please do not hesitate to contact the writer.

Yours sincerely



Sue Morgan-Dethick
GENERAL COUNSEL AND COMPANY SECRETARY